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Abstract 
Cancer is frequently characterised by dysregulation of the cellular signalling 
processes that govern proliferation, survival and attachment. Understanding such 
dysregulation continues to present a challenge given the importance of protein-protein 
interactions in intracellular processes. Exploring this protein-protein interactome 
requires novel tools capable of discriminating between highly homologous proteins, 
individual domains and post-translational modifications. This review examines the 
potential of scaffold-based binding proteins to fulfil these requirements. It also 
explores protein-protein interactions in the context of intracellular signalling 
pathways and cancer, and demonstrates the uses of scaffold proteins as functional 
moderators, biosensors and imaging reagents. This review also highlights the 
timeliness and potential to develop international consortia to develop and validate 
highly VSHFLILF³SURWHRPH´scaffold-based binding protein reagents with the ultimate 
aim of developing screening tools for studying the interactome.  
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Introduction 
Cancer has six biological hallmarks, namely sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis [1]. These hallmarks 
arise from dysregulation of normal cell processes that are governed by complex 
networks of proteins [2], a detailed understanding of which will provide new 
therapeutic opportunities. Classically, signalling networks are viewed as a 
predominantly intracellular cascade of protein modifications [3]. However, proteins 
do not act in isolation within cells, indeed 80% of proteins act in multimolecular 
complexes [4]. The importance of protein-protein interactions (PPIs) is thus as great 
as any other biochemical function of a protein when considering its biology. 
Consequently cell signalling and the process of transduction of an external stimulus 
into a cellular response can be viewed as a series of PPIs. When considered from this 
viewpoint, intracellular signalling becomes an increasingly complex issue as a single 
protein within the pathway is likely to have multiple domains that can engage in 
distinct PPIs. For example, the epidermal-growth factor receptor (EGFR) pathway 
typically consists of 375 proteins, but has been reported to involve more than 1000 
PPIs [5]. Understanding these PPIs and their dynamic nature poses one of the major 
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challenges for cell and cancer cell biology, and provides the potential for developing 
exciting new therapeutics. 
 
PPIs can be difficult to probe with traditional small molecule approaches as they are 
frequently more dynamic, and involve larger and often relatively uncontoured 
surfaces, than conventionally targeted ligand-binding domains and enzyme active 
sites [6]. However, several approaches have been used to gain understanding of PPIs 
over the years, notably including small molecule approaches [7, 8], as well as the use 
of peptides and proteins such as antibody fragments [6, 9-11]. A substantial 
proportion of this work focuses on modulating PPIs at the initiation of cell signalling, 
by targeting membrane proteins and their interacting ligands as these are readily 
accessible [11, 12]. Membrane proteins, however, only account for a small number of 
the PPIs in a signalling pathway and their inhibition may not have clinical effects as 
alterations frequently occur downstream of pathway initiation. However, targeting 
intracellular PPIs presents a more difficult set of challenges, as the cytoplasm of cells 
is a reducing environment [13] preventing disulphide bridge formation which can 
sometimes limit the use of antibodies and their derivatives. In addition, families of 
intracellular proteins frequently consist of highly homologous domains that can be 
difficult to target specifically with small molecules and thus leading to undesirable 
off-target effects [14].  Within the last decade great strides have been made to address 
such issues and here we focus on the newest approach employed to modulate PPIs 
within cells - the use of artificial binding proteins and specifically non-Ig, scaffold-
based binding proteins (SBPs).  Nanobodies are not covered in this review as, despite 
meeting many of the criteria that define SBPs, they derive from Igs. SBPs are small 
proteins, typically 10-20kDa and with a fixed stable scaffold that constrains variable 
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regions that may be introduced either by varying existing sequences within the 
scaffold or by introducing longer loop insertions. The introduction of such variability 
generates libraries of variants from which specific binders for a defined target protein, 
protein domain or modification (Figure 1) may be selected usually by phage or 
ribosomal display.  
Box 1. Scaffold-based binding proteins.  Scaffold-based binding proteins (SBPs) are 
small monomeric proteins, typically less than 200 amino acid residues, consisting of a 
stable scaffold and one or more regions of randomised residues. The scaffolds have a 
variety of parent proteins (see Table 1 for examples), but have several commonalities 
as they comprise single or repeated domains that frequently lack cysteine residues, 
meaning they can easily be expressed in bacterial systems and mammalian cells, and 
display high thermostability [11, 15-19]. SBPs frequently bind their targets with low 
nM and pM affinitiesy [17, 20]. 
 
The small size of SBPs means rapid tissue distribution and elimination occurs in vivo 
which is advantageous for diagnostic imaging, but not ideal for therapeutic use [21]. 
However SBPs can be site-specifically conjugated to a number of molecules including 
PEG which increases their half-life [22]. Immunogenecity is another concern for 
SBPs derived from non-human scaffolds [17]. 
 
To date 20 different scaffolds have been used in a variety of applications from 
crystallization chaperones and antibody replacements in basic research to diagnostics 
and biopharmaceuticals [11]. Here we focus on a subset of SBPs that have been used 
to target intracellular signalling proteins (Table 1 and Figure 1) (For a 
comprehensive review of all 20 SBPs and their uses the reader is directed to [11]). 
SBPs present advantages over other protein-based approaches in the reducing 
intracellular environment as they frequently have no cysteine residues [11] and are 
small proteins that can be easily delivered by standard cell biology techniques 
including transient transfection, viral transduction, or even modified to be cell-
penetrating proteins [20]. These properties make SBPs exciting tools for exploring 
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PPIs in the context of intracellular signalling networks and to identify new therapeutic 
targets for cancer as illustrated below. 
 
SBPs and Receptor-Tyrosine Kinase initiated pathways 
Receptor-tyrosine kinase (RTK) signalling has important roles in the control of 
fundamental cellular activity including proliferation, differentiation, migration, 
metabolism and survival [49] (Figure 2) and frequently underlies changes in cell 
behaviour associated with cancer [2]. To this end SBPs have been isolated against a 
number of receptor tyrosine kinases that are readily accessible due to their 
extracellular domains, and some of these have entered Phase III clinical trials [11, 12]. 
Here we focus on the use of SBPs to modulate intracellular signalling cascades 
downstream of activated RTKs as these are particularly challenging due to their 
intracellular nature. SBPs can also be used as imaging reagents against intracellular 
proteins as recently reviewed by Bedford et al. [50] although this topic is not covered 
here. 
 
Mitogen-Activated Protein Kinase Pathway 
The mitogen-activated protein kinase (MAPK) pathway (Figure 2) can be considered 
WKH ³FODVVLFDO´ VLJQDO WUDQVGXFWLRQ SDWKZD\ DQG remains the most studied [51]. 
Dysregulation of this pathway occurs in about one third of all human cancers [51] and 
the Ras family members (H-Ras, K-Ras and N-Ras) are key in this transduction 
cascade. These proteins are small GTPases which cycle between inactive GDP-bound 
and active GTP-bound forms (Figure 3). Ras isoforms are mutated in approximately 
30% of all human cancers, commonly causing decreased hydrolysis of GTP leading to 
constitutive activation [52], in theory making Ras an excellent candidate for anti-
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cancer drugs. Unfortunately, Ras has proved to be a particularly difficult protein to 
modulate by traditional drug development approaches and to date no drugs have 
successfully progressed through clinical trials [52], resulting in Ras being labelled an 
µXQGUXJJDEOH¶SURWHLQ. This label has arisen for a number of reasons including the pM 
affinity for GTP and that Ras has more than one mechanism to localise to the plasma 
membrane [19]. This failure to date has made it an attractive but challenging target for 
a number of research groups who work with SBPs [52].  
 
The premise that SBPs may be used to target Ras and other intracellular proteins has 
developed from the use of a single chain variable fragment of an antibody (ScFv), 
termed DQ ³intrabody´ [53].  This was then followed by inhibition of Ras 
intracellularly with the small protein, iDab6 (a single VH protein similar to a 
nanobody)[54]. X-ray crystallography revealed that iDab6 binds in the switch 1 
region of H-Ras and prevents the binding of the Ras effector protein Raf1 (cRaf). 
Functional inhibition was shown in vitro and in vivo using retroviral expression of 
iDab6 which rescued transformed NIH3T3-EJ cells and tumour formation in nude 
mice.  
 
Subsequent to these proof of concept studies, Affibodies (SBPs derived from 
staphylococcal Protein A [16])  have been isolated that also inhibit the Ras:Raf1 
interaction in biochemical assays [24] and that displayed low to mid-nanomolar 
binding affinities for Ras and Raf1. However, only those Affibodies that were isolated 
against the Ras-binding domain of Raf1 showed dose-dependent inhibition of the 
Ras:Raf1 PPI in real-time biospecific interaction analysis [24]. Unexpectedly, the 
Affibodies that showed binding to Ras had no effect in this assay. Interestingly, both 
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the Ras and Raf-binding Affibodies demonstrated effectiveness at reducing tumour-
necrosis factor-Į 71)Į)-induced interleukin-6 (IL-6) and prostaglandin E2 
production in synovial cells when introduced by either plasmid or protein transfection 
[23]. In addition, one Affibody, ZRas220, was shown to inhibit the signal transduction 
associated with 71)Į VWLPXODWLRQ E\ UHGXFLQJ SKRVSKRU\ODWLRQ RI GRZQVWUHDP
extracellular signal-regulated kinase (ERK). The Raf1 Affibody also reduced MH7A 
cell proliferation when delivered as a purified protein, but failed to mediate this effect 
when introduced in an expression plasmid, despite detectable protein expression [23]. 
It is interesting that although the Raf1-binding Affibody inhibits the Ras:Raf 
interaction, it has little effect on ERK activation and its effects on cell proliferation 
are dependent on delivery method and thus may depend on total levels of the 
Affibody which were not compared in this study, indicating that further work is 
needed to fully elucidate the mechanism and specificity of these inhibitors. 
 
The development of novel Ras protein inhibitors has been further investigated by the 
work of Spencer-Smith et al.[44] who developed a monobody, NS1 (with a scaffold 
derived from the 10th domain of fibronectin (Table 1) [18]), that binds to H-Ras and 
K-Ras irrespective of their nucleotide status.  In a separate study DARPins (based on 
an ankyrin repeat scaffold (Table 1) [17]) were isolated, with K27 and K55 
respectively inhibiting nucleotide exchange and the Ras:Raf interaction [32].  These 
studies further highlight the importance of the Ras:Raf PPI, as NS1 binds at a novel 
allosteric site, WKH Į4-ȕ6-Į5 region, leading to disruption of Ras dimerization and 
nanoclustering at the plasma membrane, preventing the binding of cRaf/bRaf [44]. 
DARPin K55 interacts with both switch regions and its binding to the switch 1 region 
resembles that of Raf, and directly competes for Raf binding [32]. In a similar manner 
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to iDab6 and the Ras:Raf Affibodies these binders have been characterised in cell-
based assays and show inhibition of downstream phosphorylation of ERK and AKT 
[32] and also block Ras-driven transformation when expressed in cells [32, 44]. Even 
more exciting is the ability of DARPin K27 to inhibit nucleotide exchange. With a 
binding affinity of 4nM for GDP-loaded Ras, this inhibitory ability appears to be due 
to binding to a region very similar to that of the nucleotide exchange factor Sos, but 
without causing the conformational change to the switch 1 region that is mediated by 
Sos binding. CRQVHTXHQWO\.ELQGLQJ³WUDSV´5DVLQDn inactive conformation [44]. 
It will be interesting to see whether other SBPs can inhibit nucleotide exchange in 
similar ways. This work on Ras/Raf has provided important insights into Ras biology, 
which has recently been supplemented by the development of a monobody inhibitor 
of isoprenylcysteine carboxyl methyltransferase, the final protein involved in the 
maturation of Ras [48], demonstrating that SBPs represent useful tools for targeting 
intracellular proteins both in vitro and in vivo, and showing that intracellular 
modulation of Ras is not as intransigent a problem as previously thought.  
 
In addition to Ras, SBPs have been isolated against upstream adaptor proteins that 
link RTK-activation to Ras and against other effector proteins downstream of Ras. 
For example, Affimer proteins (SBPs based on plant protein phytocystatin and human 
Stefin A (see Table 1) [19, 28]) have been generated against a number of Grb binding 
proteins [25] showing high selectivity of binding between isoforms that have 
approximately 70% sequence identity [55]. These Affimer reagents are specifically 
targeted to the Grb SH2 domains and are able to isolate their respective full length 
Grb proteins from U-2 OS cell lysates and are currently being tested for intracellular 
activity [25].  
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Downstream of MEK, the MAPK pathway diverges to three families of closely 
related effectors, ERK, JNK or p38 (Figure 2), all of which have been used to isolate 
SBPs, although p38 has yet to be followed up by intracellular studies [29, 37, 43]. 
Both monobody and DARPin binders have been selected against ERK2, and show 
low nM binding affinities as well as specificity for ERK2 over JNK and p38 proteins 
[28-30]. The monobody binders demonstrated inhibition of phosphorylation of the 
downstream protein Elk1 when co-transfected into HEK293 cells that were 
subsequently stimulated with epidermal growth factor (EGF), but did not inhibit 
phosphorylation of ERK2 itself. Interestingly they were functional at the whole 
organism level, leading to formation of multiple vulva in C. elegans transfected with 
constructs that express monobodies. This developmental process involves loss of 
function of the ERK homologue Ce-MPK-1 [43]. DARPin binders have taken ERK2 
recognition further with versions identified that can distinguish between ERK2 in its 
unmodified conformation and in its phosphorylated conformation and displaying low 
nanomolar KD values for their respective conformers [37]. The ability of these binders 
to function intracellularly was tested by bioluminescence resonance energy transfer 
(BRET) in COS7 cells with an increase in BRET signal observed for the pERK2 
specific binder when the cells were stimulated with serum [37]. Subsequently, this 
binder has been developed for use as a biosensor in live cell assays with the addition 
of a merocyanine dye that demonstrated localisation of pERK2 in the nucleus of 
serum-stimulated NIH3T3 cells [36]. This work shows that SBPs can detect the 
smallest but arguably one of the most important protein modifications in live cells and 
can provide functional read-outs to allow monitoring of real-time pathway activation. 
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DARPin binders for the c-Jun N-terminal kinase (JNK) family of proteins have also 
been identified [33]. This family of proteins has three members JNK1, JNK2 and 
JNK3 each with multiple isoforms that share 80% homology at the protein level [56]. 
Whilst small molecule inhibitors that display low nM binding affinities are available 
for the JNKs, they cannot distinguish between the three family members [57]. By 
contrast the DARPin binders show isoform specificity between the JNK1 and JNK2 
isoforms and also possess the desirable characteristics of a 1:1 binding ratio and low 
nM affinities. In addition, they can inhibit phosphorylation of JNK and its 
downstream effector c-Jun [33]. The ability of these DARPins to bind the specific 
JNK isoform endogenously was again demonstrated by BRET in HEK293 cells. 
Intracellularly they retained their isoform specificity and ability to inhibit JNK 
phosphorylation [33]. To date several key members of the MAPK pathway have been 
targeted, demonstrating the utility of SBPs to probe and modulate intracellular 
signalling pathways with high specificity but without altering the levels of the 
endogenous target protein. 
 
 Phosphoinositide 3-kinase pathway 
The phosphoinositide 3-kinase (PI-3K) pathway is a parallel pathway to MAPK that 
can be activated by RTKs, GPCRs or by Ras (Figure 2). Given that this pathway also 
regulates cell proliferation and survival, it is not surprising that it is one of the most 
commonly activated pathways in cancer [58]. The ability of SBPs to modulate 
components of this pathway have not yet been assessed in detail, with SBPs only 
isolated against PI-3K. This kinase is a heterodimer consisting of a p110 catalytic 
subunit and a p85 regulatory subunit, both of which have multiple isoforms [58]. 
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Affimer reagents have been developed to bind to the p85 subunit of PI-3K including 
those specific for the N-terminal SH2 domain of thH S Į-isoform. These binding 
proteins show not only isoform specificity, but also domain specificity as they do not 
cross-react with the C-terminal SH2 domain within the same protein [25]. These 
Affimers can block p85 function intracellularly as demonstrated by increased Akt 
phosphorylation in transfected NIH3T3 cells but without disrupting the formation of 
the p85:p110 complex [25]. This further demonstrates the ability of SBPs to inhibit 
function without disrupting protein complex formation and/or scaffolding function, a 
property that is likely to be important in dissecting some regulatory pathways.  
 
Src Signalling 
Domain-specific binding illustrates why SBPs represent a new way to complement 
existing approaches to the study of protein function. Their ability to target individual 
domains within endogenous proteins should allow determination of the role of those 
domains in protein function and signalling cascades. An example of this is shown by 
SBPs that have been selected against SH3 and SH2 domains for several members of 
the Src family of proteins [38-42]. This family of non-receptor tyrosine kinases has 
nine members, Src, Yes, Fyn, Fgr, Yrk, Lyn, Blk, Hck, and Lck, that contain both 
SH2 and SH3 binding domains in addition to their kinase domain and an SH4 domain 
[59]. Activation of Src is a feature of multiple cancers including breast, pancreatic, 
liver, lung and colorectal cancer [60]. Indeed 80% of colorectal cancers have elevated 
Src levels [61], while Yes and Lck have also been implicated in this disease [62]. The 
relevance of this protein family as cancer targets can be seen from the number of 
small molecule inhibitors currently undergoing clinical trials, despite the fact that 
such inhibitors show only modest effects when used as a monotherapy [63]. This 
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highlights the need for development of further more potent and selective means to 
studying PPIs. The ability of SBPs to specifically block a particular domain without 
affecting protein level will ultimately aid in identifying functionally important 
domains and potentially provide novel therapeutics in their own right, or define new 
target sites for small molecule design. 
  
Monobody reagents have been identified that bind with high specificity and nM 
affinities to either the SH3 or the SH2 domains within several family members, 
notably Src, Fyn, Lyn and Lck, [38-42]. The majority of the SH3-binding reagents 
contained the classical proline-rich SH3 binding motif xxPxxP whereas the SH2 
binding reagents were strongly antagonistic to the substrate pYEEI, but did not show 
a consensus sequence [38-42]. Interestingly, specificity was greater for the SH3 
monobody that lacked the consensus sequence, whilst the binder displaying the 
highest affinity showed a degree of cross-reactivity to a number of family members, 
namely Yes, Fyn, Lyn and Lck [41]. The most potent SH3 binders for Src, Fyn and 
Lyn could bind their respective targets in cell lysates [39-41], but not all binders 
altered the function of their target as assessed by kinase assay [38, 39]. The utility of 
WKHVHµQRQ-DFWLYH¶ELQGHUVZDVVXEVHTXHQWO\H[SORUHGDQGWKHPRVWSRWHQt of Src SH3 
binders, 1F11, which bound with similar affinity to Src intracellular binding partners, 
was found to preferentially bind activated Src, as the SH3 domain is more exposed in 
this conformation [38]. These characteristics mean that it is ideally suited for 
biosensor development and its use as an intracellular fluorescence biosensor was 
demonstrated by attaching an mCerulean tag and modifying the scaffold backbone for 
use in live cell imaging [35].  This novel biosensor was used to monitor Src 
localisation at the cell membrane in PDGF-stimulated mouse NIH3T3 cells, a difficult 
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location to monitor with good spatiotemporal resolution, leading to the finding that 
activated Src has an important role in ruffle formation and movement [38]. In contrast 
to the SH3 binders that have been tested intracellularly and shown to be inactive, the 
monobody binders for the SH2 domains in the Src family do show intracellular 
activity. Most recently, an Lck binder has been reported to cause a decrease in 
phosphorylation of downstream protein Zap70 in stimulated Jurkat cells [42]. These 
various studies demonstrate that SBPs can bind specifically to individual, highly 
homologous domains in proteins, and mediate functional effects intracellularly. 
 
Wnt signalling 
The Wnt signalling pathway has fundamental roles in embryonic development and 
regulates processes as diverse as cell fate determination, axis formation and 
organogenesis [64]. Over the last 20 years it has become clear that Wnt signalling is 
dysregulated in a number of cancers, notably colorectal but also breast and 
hepatocellular cancer [65]. This pathway has been targeted with monobody binders 
against ȕ-catenin and dishevelled (Figure 2) [45]. A ȕ-catenin binder, B8, showed 
inhibition in a TOPflash reporter assay in HEK293 and DLD1 colorectal cancer cells 
and this translated to in vivo inhibition of Drosophila wing disc development [45]. 
This work provides a further demonstration of the range of pathways that can be 
modulated by SBPs. 
 
Apoptosis 
Evasion of apoptosis and cell death is a key hallmark of cancer and is usually the 
result of a change in the balance of anti-apoptotic and pro-apoptotic signals [1]. SBPs 
have been developed to target both of these forms of signal with Alphabodies selected 
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against the anti-apoptotic Mcl-1 [20] and DARPins against the pro-apoptotic caspases 
[31]. Alphabodies,  artificial SBPs of three anti-parallel helices [15], targeting Mcl-1, 
an anti-apoptotic member of the Bcl-2 family that sequesters the pro-apoptotic Bax 
[66], show pM binding affinities [20]. Mcl-1 is implicated in a number of cancers 
including myeloid leukaemia and breast cancer [67] and when tested in NCI-H929 
bone marrow cells, the Alphabodies reduced cell viability with IC50 values of 0.5-2 
µM [20]. This translated to in vivo mouse models with 33% tumour inhibition 
compared to vehicle controls [20].  In comparison with other SBPs, Alphabodies are 
cell-penetrative without the need for a plasmid-based delivery mechanism, 
demonstrating how some SBPs have the potential to be more readily translated to the 
clinic. 
 
Caspases are a homologous family of proteases that function as the intracellular 
effectors of apoptosis. They have been targeted by DARPin binders against the 
various caspases with the exception of caspase 4 [48].  However, not all of the binders 
were able to modulate caspase function, demonstrating that inhibition/activation is not 
a prerequisite of binding and emphasising the importance of performing functional 
assays before undertaking studies to examine SBPs¶ intracellular properties. Indeed, 
functional assays can provide insights into the mode of action of SBPs and which may 
consequently affect the likelihood that a particular SBP will display intracellular 
effectiveness. For example, the caspase 2 inhibitory DARPin has an allosteric effect 
that stabilises the enzyme in an inactive conformation [35].  By contrast, the caspase 3 
DARPins show competitive inhibition [34] and very similar Ki values to small 
molecule inhibitors of caspase 3, but greater Ki than the natural substrate XIAP [68]. 
The caspase 7 binding DARPins show a third mode of action by inhibiting the 
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cleavage of procaspase 7 to its active caspase 7 form [30]. The caspase 3 and caspase 
7 inhibitory DARPins have been tested in combination for in vitro functionality in 
HeLa cells and showed the ability to reduce by 70-80% both caspase 3 and 7 activity 
against the synthetic substrate DEVD [30]. This work shows that pro-apoptotic 
proteins can be targeted by SBPs which will be useful for addressing diseases 
characterised by overactive apoptotic pathways, such as autoimmune diseases [69]. 
However, in their current format these binders do not have direct applications for 
informing cancer therapeutics as they are targeted to inhibit apoptosis, which is a 
hallmark of cancer where SBPs that activate apoptosis would be more beneficial. 
 
 
Other cancer protein targets 
SBPs have also been isolated against other intracellular proteins and post-
translocation modifications (PTMs) implicated in cancer, including monobodies 
against the SH2 domain of Abl kinase [70, 71], DARPins against tubulin caps [72] 
and Affimers and monobodies against sumoylated and ubiquitnated proteins [26, 27, 
46, 47]. Abl kinase is a non-receptor tyrosine kinase that links external stimuli to 
cellular responses, notably proliferation, migration and survival [73]. Abl is 
frequently found as a component of fusion proteins in leukaemias and is responsible 
for transformation in these cells, but it also occurs in solid tumours with links to 
resistance in these tumours [73].  Small molecule inhibitors do exist as clinical 
therapies for Abl-fusion-associated leukaemias, however, they are not specific for Abl 
and cross-react with other tyrosine kinases [73]. By contrast, the Abl binding 
monobody, HA4, shows highly specific binding for the SH2 domain of Abl [71]. HA4 
has inhibitory effects on phosphorylation of a downstream kinase, paxillin, and 
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reduced STAT activation when expressed in HEK293 and K562 cells respectively 
[71]. The effectiveness of this binder was then enhanced by combination with a 
second binder targeting a distinct epitope to form a tandem binder fusion that has the 
ability to induce apoptosis in both the K562 cell-line and peripheral blood cells from 
patients with chronic myeloid leukaemia [70].   
 
Tubulin is a critical cytoskeletal protein that has important roles in mitosis, governing 
spindle formation and the correct separation of chromosomes. Inhibition of tubulin 
can induce apoptosis and cell death and tubulin-binding agents have been used as 
cancer therapeutics for almost 50 years [74]. However, resistance to these agents 
occurs and the mechanisms by which they induce apoptosis are not fully understood 
[74]. SBPs have the potential to address these issues. For example, the DARPin 
ELQGHU ' ELQGV WKH ORQJLWXGLQDO LQWHUIDFH ȕ-subunit of tubulin and inhibits tubulin 
assembly in a biochemical assay [72]. A tandem fusion of two molecules of this 
binder was shown to inhibit tubulin growth at the + end of microtubules and to induce 
tubulin depolymerisation in Xenopus egg extract [72]. This depolymerisation due to + 
end binding is similar to that mediated by the clinically used tubulin-binding agent 
vinblastine [75] that has a number of side-effects. SBPs could be used to further 
understand the mechanism of action of tubulin-binding agents. 
 
In addition to targeting specific signalling proteins SBPs have been developed to 
probe PTMs that can mediate signal transduction, notably sumoylation and 
ubiquitnation (Figure 4). Both are functionally important in a variety of cancers 
modifying well-known tumor suppressors and oncogenes such as p53 and mTOR [76-
78]. The ability to modulate these processes is providing valuable insights into cancer 
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biology. To this end Small Ubiquitin-like Modifier (SUMO) proteins have been 
targeted by both monobodies and Affimers to disrupt the SUMO/SIM (SUMO-
interacting motif) interactions with reagents identified that bind in vitro with isoform 
specificity and nM affinities [26, 47]. These reagents show co-localisation with the 
appropriate SUMO isoforms in the nuclei of transfected HEK293 cells and the ability 
to pull-down SUMO isoforms from cell lysates [26, 46]. Despite these similarities, 
there is one important difference between these reagents - the monobodies inhibit 
SUMO conjugation whilst the Affimers do not [26, 47], making the latter potential 
more useful for assessing the impacts of the SUMO/SIM PPI. 
 
Another important PTM is ubiquitination which not only serves to target proteins for 
degradation, but can also play important roles in cell signalling that are only just 
being delineated [77, 78]. Ubiquitination can occur as both monoubiquitination and 
polyubiquitination, the latter having eight linkage variants (Figure 4B). To enable the 
study of these variations of polyubiquitination, it is necessary to have linkage-specific 
reagents and to date specific antibodies only exist for five variants; subsequently 
SBPs could be identified for the remaining linkages [27]. Indeed Affimers have been 
identified to specifically target two of these untargeted linkages, K6 and K33, with 
pM affinities. These reagents identified specifically assembled ubiquitin chains in 
vitro and from cell lysates, especially when used in dimeric forms. The K6-specific 
Affimers also co-localised with TOM20, a protein known to be polyubiquitinated at 
this linkage, in HEK293 cells [27]. Pulldown of K6-linked proteins from HEK293 
lysate with this Affimer followed by shotgun proteomics identified a number of 
proteins, including HUWE1 which is overexpressed in several cancers [27, 79], 
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highlighting the utility of these reagents for gathering further insights into this 
signalling pathway. 
 
Conclusion 
 
SBPs represent a new avenue to assist in dissecting signalling pathways and exploring 
cancer biology. As described here they have the ability to bind in a highly specific 
manner to proteins that engage in PPIs and to PTMs in the intracellular environment.  
They have the functional capacity to act as modulators, intracellular biosensors and as 
imaging reagents.  They present advantages over other methods for exploring PPIs as 
they can be rapidly generated in vitro, display high specificity and can bind to sites 
other than binding pockets that are commonly the target for small molecule effectors. 
As the protein-SURWHLQ ³LQWHUDFWRPH´ KDV EHHQ UHSRUWHG to involve some 650,000 
interactions [6], there is a clear imperative to generate selective probes to facilitate 
study of PPIs, particularly in relation to diseases, including cancer. We argue that 
SBPs represent such selective tools. There is now a need to develop catalogues of 
validated SBPs that target proteins involved in PPIs of importance in diseases such as 
cancer. There are examples of such development and validation for antibodies by 
international consortia, including the Structural Genomics Consortium and Human 
Protein Atlas [80, 81].  It is now timely to develop international consortia to develop 
and validate KLJKO\VSHFLILF³SURWHRPH´UHDJHQWV based on SBPs. The novelty of SBPs 
is that, in addition to providing highly specific recognition reagents, they can be used 
as intracellular probes and modulators. Ideally SBPs can be configured to allow 
simple direct intracellular delivery to facilitate rapid high throughput screening for 
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functional clones. Such biotechnological advances will ultimately improve target 
validation and provide important tools for the drug discovery pipeline.  
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Figure Legends 
Figure 1. Scaffold-based binding proteins. A) Structure of the SBPs discussed in 
this review, showing a variety of different scaffolds with different binding domains 
shown in orange. These examples are an Affibody against HER2 (PBD: 3MZW), the 
Affimer scaffold (PBD: 4D6T), an Alphabody against IL23 (PBD: 5MJ4), a DARPin 
against IL4 (PBD: 4YDY) and a monobody against SH2 (4JRG). B) Structures of the 
SBPs shown in complexes with a relevant target protein, with the exceptions of the 
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Affibody and Alphabody as these have not been crystallised with signalling proteins 
to date. These examples are an affibody with HER2 (PBD: 3MZW), an Affimer with 
SUMO (PBD: 5ELJ), an Affimer with diubiquitin (PBD: 5OHV), an Alphabody with 
IL23 (PBD: 5MJ4), a DARPin with K-Ras (PBD: 502T) a DARPin with ERK2 (PBD: 
32U7) and a monobody with H-Ras (5E95). (DARPin - Designed Ankyrin Repeat 
Protein).  PyMOL (Schrödinger, LLC, New York, NY) was used to create structural 
diagrams. 
 
Figure 2. Common intracellular signalling pathways. Illustration of the five major 
pathways discussed in this review. The RTK activated pathways of MAPK in purple, 
PI3K pathway in green, and SRC in pink, which can also be activated by integrins and 
GPCRs (not shown). The canonical Wnt pathway is shown in orange, while the 
apoptotic pathways are shown in yellow. Scaffold-based binding proteins have been 
selected against the proteins shown in bold. (Dsh ± GLVKHYHOOHGȕ-cat ±ȕ-catenin). 
 
Figure 3. Ras - A molecular switch. K-Ras (green) acts as a molecular switch, 
cycling between inactive GDP-bound, shown associated with catalytic domain of the 
guanine exchange factor Sos1 (light pink), and active GTP-bound form shown in 
complex with RBD region of Raf1 (orange). The switch regions of K-Ras are shown 
in yellow (switch I) and red (switch II) respectively with the NS1 monobody interface 
(Į4, ȕ6, Į) highlighted in blue.  GTP is shown in cyan and Mg2+ ion as a hot pink 
sphere. Ras-Sos structure PDB: 1XD2, Ras-Raf structure PDB: 3KUD. 
 
Figure 4. Sumoylation and ubiquitination. A) The processes of SUMO and 
ubiquitin conjugation to a target protein are very similar, as shown with 
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SUMO/Ubiquitin binding to an E1 activating enzyme followed by transfer of the 
SUMO/Ubiquitin protein to an E2 conjugating protein and then an E3 ligase 
completing the transfer to the target protein. Target proteins are deubiqutinated or the 
SUMO protein deconjugated by DUB and SENP enzymes respectively [76, 77]. B) A 
ribbon diagram (PBD: 1UBQ) showing the 8 locations that ubiquitin linkages can 
form and a selection of their delineated functions [77]. (SUMO ± Small Ubiquitin-like 
Modifier; Ub ± Ubiquitin; DUB ± deubiquitinating enzyme; SENP - SUMO specific 
protease). 
